Vitura Health Ltd (VIT) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Vitura Health Ltd A$0.05, price A$0.02, upside +119.1%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Vitura Health Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range A$0.0190 – A$0.9353 · fair‑value band A$0.0320 – A$0.0700 · the A$0.0210 price screens below the A$0.0460 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Vitura Health in your weekly email
Every Wednesday you see whether Vitura Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services.
Show more
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a therapy clinic that offers telehealth consultations. It also offers psychedelics under the Cortexa brand; Adaya which provides hybrid formulations and Australian-cultivated products; candor medical that provides care to patients; and inscape, which offers crafted formulations for individual needs. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. Vitura Health Limited was incorporated in 2018 and is based in South Yarra, Australia.
Stock analysis
Vitura Health Ltd (VIT) currently trades at A$0.0210, while our model-based Fair Value estimate is A$0.0460, implying the stock looks roughly 54.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of A$0.2300 per share, and 24 of the 24 models we run sit above the A$0.0210 price.
Bear case: the Asset-Based group reads lowest at A$0.0500, and 0 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: A$0.0320 (bear) to A$0.0700 (bull), the price of A$0.0210 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vitura Health Ltd reported revenue of A$124M in FY2025 versus A$21.7M in FY2021, a compound +54.6%/yr. Reported net income was A$3.3M in FY2025.
Key figures
Market cap A$20.5M (≈ $14.5M) · P/S ratio 0.16 · Dividend yield 9.5% · Net margin 2.7% · Return on equity 1.2% · Return on assets (EBIT) 18.5% · Operating margin −0.1% · Revenue (TTM) A$129M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 70% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 119%, VIT screens cheaper than that median.
Fair Value models
Bear A$0.0320Fair Value A$0.0460Bull A$0.0700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.8%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+201.8%
’17
’18
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−23.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−33.2%
Dividend (yield on the price)9.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3,089% → 4%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about −16.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 631 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+130% · Top 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets2% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)0% · Bottom 25%
Growth and dividend
Revenue growth8% · Above median
Dividend yield (TTM)9.5% · Top 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vitura Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/VIT
Frequently asked questions
Is Vitura Health Ltd (VIT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.0460 versus a price of A$0.0210, about +119% upside (undervalued).
What is the fair value of VIT?
Our model-based fair value for Vitura Health Ltd is A$0.0460 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.0210.
What is the quality score of VIT?
Vitura Health Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vitura Health Ltd (VIT)?
Our model-based price target is the fair value of A$0.0460 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario A$0.0320, optimistic scenario A$0.0700. It is a calculation from audited fundamentals, not an analyst target.
What is the Vitura Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0460, about +119% upside versus a price of A$0.0210 (undervalued). Cautious scenario A$0.0320, optimistic scenario A$0.0700. The calculation is refreshed regularly with new filings.
What is the revenue of Vitura Health Ltd (VIT)?
Vitura Health Ltd reported trailing-twelve-month revenue of about A$129M (latest available figure, as of Sep 23, 2026).
Does Vitura Health Ltd pay a dividend?
Vitura Health Ltd currently shows a dividend yield of about 9.52% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Vitura Health Ltd (VIT)?
For today's price to be fair in a discounted-cash-flow model, Vitura Health Ltd would have to grow free cash flow by -13.9 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +298.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of VIT use?
Our models discount Vitura Health Ltd at 9.5 %: a base by market capitalisation (nano), country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vitura Health Ltd that is -13.9 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Vitura Health Ltd (VIT) delivered so far?
Over the past 5 years revenue at Vitura Health Ltd grew +298.2 % a year. The price currently implies -13.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vitura Health Ltd (VIT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Vitura Health Ltd (-13.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vitura Health Ltd (VIT)?
The free-cash-flow yield on the price is 20.18 %: that much free cash flow Vitura Health Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vitura Health Ltd (VIT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vitura Health Ltd it is A$0.0460 per share (as of Sep 23, 2026), against a price of A$0.0210. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Vitura Health Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, VIT trades below its calculated fair value: price A$0.0210, fair value A$0.0460, a gap of about +119% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIT?
No. The price is what the market pays today (A$0.0210); the fair value is what the company's own numbers justify (A$0.0460). For Vitura Health Ltd the two are A$0.0250 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vitura Health Ltd worth?
The market values Vitura Health Ltd at about A$20.5M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.0210; our models calculate a fair value of A$0.0460 per share.
What do the bullish and bearish scenarios say about VIT?
Our models span a range for Vitura Health Ltd: cautious scenario A$0.0320, base A$0.0460, optimistic A$0.0700 per share (as of Sep 23, 2026, price A$0.0210). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vitura Health Ltd (VIT)?
Balance-sheet figures for Vitura Health Ltd (as of Sep 23, 2026): return on equity 1.2%, debt of 0.14 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is VIT from its 52-week high?
Vitura Health Ltd trades at A$0.0210, about 70% below its 52-week high of A$0.0710 and 11% above the low of A$0.0190 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0460 is for.
Which stocks are comparable to Vitura Health Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vitura Health Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.0210, calculated fair value A$0.0460 (+119%), Quality Score 35/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VIT calculated?
We run Vitura Health Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0460, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Vitura Health Ltd currently trades 119 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vitura Health Ltd (VIT)?
The closing price on Sep 24, 2026 was A$0.0210. Our model-based fair value is A$0.0460, about +119% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vitura Health Ltd right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (A$0.0320). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.0320 to A$0.0700) leaves room in how you read the outcome.
Key figures of Vitura Health Ltd
How large is the market capitalisation of Vitura Health Ltd (VIT)?
The market capitalisation of Vitura Health Ltd is A$20.5M (≈ $14.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vitura Health Ltd (VIT)?
The price-to-sales ratio of Vitura Health Ltd is 0.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Vitura Health Ltd (VIT)?
The dividend yield of Vitura Health Ltd is 9.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vitura Health Ltd (VIT)?
The net margin of Vitura Health Ltd is 2.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vitura Health Ltd (VIT)?
The return on equity (ROE) of Vitura Health Ltd is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vitura Health Ltd (VIT)?
On an EBIT basis the return on assets of Vitura Health Ltd is 18.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vitura Health Ltd (VIT)?
The operating margin of Vitura Health Ltd is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vitura Health Ltd (VIT)?
Revenue at Vitura Health Ltd is growing +8.3% versus a year earlier (3y avg +22.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vitura Health Ltd (VIT)?
Earnings per share at Vitura Health Ltd are growing +515% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vitura Health Ltd (VIT) carry?
The net debt of Vitura Health Ltd is A$4.4M (fiscal year 2025, ≈ 1.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vitura Health Ltd in the live analysis
One click puts Vitura Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
